HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency
- 1 August 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 146 (2), 447-450
- https://doi.org/10.1016/j.jaci.2020.03.043
Abstract
No abstract availableFunding Information
- Children's Cancer and Leukaemia Group (CCLGA 2017 16)
- The Little Princess Trust
This publication has 8 references indexed in Scilit:
- Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical ClassificationJournal of Clinical Immunology, 2020
- Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working GroupFrontiers in Immunology, 2018
- Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network RegistryJournal of Allergy and Clinical Immunology, 2018
- Hematopoietic cell transplantation in primary immunodeficiency – conventional and emerging indicationsExpert Review of Clinical Immunology, 2018
- Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disordersJournal of Allergy and Clinical Immunology, 2018
- Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options – a Retrospective AnalysisJournal of Clinical Immunology, 2015
- Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantationBlood, 2007
- Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteriaHistopathology, 2001